Puma Biotechnology, Inc. (PBYI)
NASDAQ: PBYI · IEX Real-Time Price · USD
5.13
-0.04 (-0.77%)
At close: Apr 23, 2024, 4:00 PM
5.25
+0.12 (2.34%)
After-hours: Apr 23, 2024, 6:45 PM EDT
Puma Biotechnology Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Puma Biotechnology stock has a target of 7.00, which predicts an increase of 36.45% from the current stock price of 5.13.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 1, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for PBYI is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
---|---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +36.45% | Mar 1, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +55.95% | Feb 13, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +55.95% | Sep 20, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +55.95% | Aug 4, 2023 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +55.95% | Jun 5, 2023 |
Financial Forecast
Revenue This Year
223.62M
from 235.64M
Decreased by -5.10%
Revenue Next Year
221.37M
from 223.62M
Decreased by -1.01%
EPS This Year
0.27
from 0.45
Decreased by -41.07%
EPS Next Year
0.17
from 0.27
Decreased by -35.00%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 232.6M | 246.9M | 262.2M | 263.6M | 268.8M |
Avg | 223.6M | 221.4M | 220.9M | 256.0M | 261.1M |
Low | 211.7M | 182.3M | 166.6M | 246.0M | 250.9M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.3% | 10.4% | 18.4% | 19.3% | 5.0% |
Avg | -5.1% | -1.0% | -0.2% | 15.9% | 2.0% |
Low | -10.2% | -18.5% | -24.7% | 11.4% | -2.0% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 0.32 | 0.50 | 0.63 | 0.11 | -0.21 |
Avg | 0.27 | 0.17 | 0.06 | 0.10 | -0.20 |
Low | 0.23 | -0.07 | -0.29 | 0.10 | -0.20 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -30.0% | 90.0% | 265.5% | 81.7% | - |
Avg | -41.1% | -35.0% | -66.5% | 76.5% | - |
Low | -49.9% | - | - | 69.5% | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.